Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK1 | Q13464 | 1/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | CNR2 | P34972 | 6/20 | 0.42 |
| ▸ | CNR1 | P21554 | 6/20 | 0.42 |
| ▸ | CFD | P00746 | 3/20 | 0.41 |
| ▸ | TOP2A | P11388 | 1/20 | 0.41 |
| ▸ | HTR2C | P28335 | 2/20 | 0.41 |
| ▸ | HTR2A | P28223 | 1/20 | 0.41 |
| ▸ | HTR3A | P46098 | 2/20 | 0.41 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.41 |
| ▸ | HRH1 | P35367 | 1/20 | 0.41 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.41 |
| ▸ | PARP1 | P09874 | 1/20 | 0.40 |
| ▸ | GLS | O94925 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15881996 | 0.89 | CYP1A2 (0.50) | ROCK1POLBCNR2CNR1ADRA1A | |
| SCHEMBL20250813 | 0.86 | ROCK1 (0.47) | ROCK1POLBCNR2CNR1TOP2A | |
| SCHEMBL17321422 | 0.85 | ROCK1 (0.46) | ROCK1CNR2CNR1TOP2AHTR3A | |
| SCHEMBL15882102 | 0.85 | ELANE (0.53) | ROCK1CNR2CNR1HTR3A | |
| SCHEMBL17176239 | 0.84 | HTR3A (0.54) | CNR2CNR1CFDHTR3APARP1 | |
| SCHEMBL17324729 | 0.84 | CNR1 (0.44) | ROCK1CNR2CNR1CFDHTR3A | |
| SCHEMBL17324753 | 0.81 | CNR1 (0.48) | CNR2CNR1CFDHTR3APARP1 | |
| SCHEMBL17324818 | 0.80 | KDM4C (0.50) | CNR2CNR1HTR3A | |
| SCHEMBL17324730 | 0.78 | CNR1 (0.48) | CNR2CNR1HTR3APARP1 | |
| SCHEMBL29781847 | 0.78 | HSD17B10 (0.61) | ROCK1CFD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150353505-A1 | PHTHALAZINONES AND ISOQUINOLINONES AS ROCK INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2015-12-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150353505-A1 | PHTHALAZINONES AND ISOQUINOLINONES AS ROCK INHIBITORS | MYLK, MYLK2, ROCK1 | ROCK1 3/4885POLB 3821/4885CNR2 3572/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.